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Abstract. Background/Aim: Selenium-containing
compounds are becoming new alternatives in experimental
chemotherapy in order to overcome multidrug resistance in
cancer. The main goal of this study was to determine whether
combined treatment with new Se-compounds would increase
the effect of conventional doxorubicin chemotherapy in
breast cancer cell lines. Materials and Methods: Se-
compounds were evaluated regarding their cytotoxic and
apoptosis-inducing effect on MCF-7 and ATP-binding
cassette subfamily B member 1 (ABCB1)-overexpressing
KCR breast cancer cell lines. Moreover, the interaction of
Se-compounds with doxorubicin was assessed using MTT
assay. Results: selenoanhydride exerted selective activity
towards the doxorubicin-resistant KCR cell line
overexpressing ABCB1. Among the selenoesters, only ketone-
containing selenoesters exerted significant cytotoxic activity
against MCF-7 and KCR cell lines and the Se-compounds
acted synergistically with doxorubicin on the KCR cell line.
Conclusion: The importance of the COSeCH2COCH3 and
COSeCH2CO(CH3)3 moieties for the cytotoxic and adjuvant
role of Se-compounds was highlighted.
Selenium-containing compounds (Se-compounds) are
becoming a novel and promising alternative approach in the
fight against cancer: according to recent reviews in the field,
many selenium derivatives have been reported to show
antiproliferative, anticancer or cancer chemopreventive
activity in different biological assays (1, 2). The mechanisms
of action of the Se-compounds against cancer are very diverse,
as these derivatives can interact with key biological processes
such as oxidative stress, angiogenesis, and apoptosis
induction, among others (1, 2). Furthermore they possess
chemopreventive properties (3, 4). Besides their intrinsic
anticancer activity, specific selenium derivatives can inhibit
certain cancer resistance mechanisms such as the function of
multidrug resistance (MDR) efflux pumps (5, 6), or can
modulate the activity of chemotherapeutic drugs (7, 8). 
Previously our group synthesized a selenoanhydride and a
series of selenoesters (Figure 1), finding that they were
potent antiproliferative and anticancer agents (9).
Subsequently, four of these selenium derivatives
(selenoanhydride 1 and the ketone-containing selenoesters 9-
11) were described as very potent inhibitors of the ATP-
binding cassette subfamily B member 1 (ABCB1; P-
glycoprotein) efflux pump in the MDR subline of the mouse
T-lymphoma cell line L5178Y (5) and in MDR Colo 320
colon adenocarcinoma cell line (6). In addition, they
interacted synergistically with chemotherapeutic drugs such
as vincristine, doxorubicin, cyclophosphamide, methotrexate,
topotecan and 5-fluorouracil in checkerboard combination
assay on L5178Y mouse T-lymphoma cells (10). 
It has been reported that Se-compounds are less active
against MCF-7 cells compared to other tumor cell lines such
as A549, PC-3 and HT-29 (9). Herein we aimed to determine
whether combined treatment with Se-compounds and
doxorubicin would overcome this previously observed
resistance, and become thus a novel and promising approach
to fighting breast cancer.
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Compounds. The eleven Se-compounds tested (selenoanhydride 1 and
selenoesters 2-11, Figure 1) were kindly provided by Dr. Enrique
Domínguez Álvarez (Spanish National Research Council, Madrid,
Spain) and by Professor Dr. Carmen Sanmartín (University of
Navarra) (9). Se-compounds 1-11 were stable and their purity was
assessed through spectroscopic techniques (elemental analysis, nuclear
magnetic resonance, mass spectrometry and infrared spectroscopy).
Compounds 12-15 were purchased from Sigma-Aldrich (Steinheim,
Germany), respectively, to be used as non-selenium (12) isostere of
selenoanhydride (1) and as inorganic chalcogen salts (13-15), for
comparing their activity with the selenoesters. The compounds were
dissolved in dimethyl sulfoxide (DMSO).
Cell lines. Breast cancer cell line MCF-7 (ATCC® HTB-22) was
purchased from LGC Promochem (Teddington, Middlesex, UK).
The MCF-7 cell line and its drug-resistant subline KCR were grown
in Eagle’s minimal Essential medium (EMEM), containing 4.5 g/l
glucose supplemented with a non-essential amino acid mixture, a
selection of vitamins and 10% heat-inactivated fetal bovine serum.
The cell lines were incubated at 37˚C, in an atmosphere of 5% CO2
and 95% air. On every third passage, 0.56 μg/mI doxorubicin (Teva
Pharmaceuticals, Budapest, Hungary) was added to the medium in
order to maintain ABCB1 expression in KCR cells.
Cytotoxicity assay. The cytotoxic effects of the Se-compounds were
determined on MCF-7 and KCR breast cancer cell lines. The effects
of increasing concentrations of Se-compounds on cell growth were
tested in 96-well flat-bottomed microtiter plates. The compounds
were diluted in 100 μl of medium.
The adherent breast cancer cell lines were cultured in 96-well
flat-bottomed microtiter plates, using EMEM supplemented with
10% heat-inactivated fetal bovine serum. The density of the cells
was adjusted to 1×104 cells in 100 μl per well, the cells were seeded
for 24 h at 37˚C, with 5% CO2 prior to the assay, then the medium
was removed from the plates containing the cells, and dilutions of
Se-compounds previously made in a separate plate were added to
the cells in 200 μl.
The culture plates were incubated at 37˚C for 24 h; at the end of
the incubation period, 20 μl of thiazolyl blue tetrazolium bromide
(MTT; Sigma) solution (from a stock solution of 5 mg/mI) were
added to each well. After incubation at 37˚C for 4 h, 100 μI of
sodium dodecyl sulfate (Sigma) solution (10% in 0.01 M HCI) were
added to each well and the plates were further incubated at 37˚C
overnight. Cell growth was determined by measuring the optical
density (OD) at 540/630 nm with Multiscan EX ELISA reader
(Thermo Labsystems, Cheshire, WA, USA). Inhibition of the cell
growth was determined according to the formula below:
Results are expressed in terms of IC50, defined as the inhibitory
dose that reduced the growth of the cells exposed to the tested
compounds by 50%. 
The selectivity was calculated using the selectivity index (SI),
which is defined as the quotient of the IC50 value determined for
the non-tumorous MRC-5 cell line described previously (6) to the
IC50 value for the respective cancer cell line (MCF-7 or KCR).
Following the criteria reported in bibliography (6), we considered
a compound to be strongly selective when its SI was 6 or higher.
Compounds with SI values of 1-3 and 3-6 were regarded as slightly
and moderately selective, respectively.
Checkerboard combination assay. A checkerboard microplate
method was applied to study the effect of drug interactions between
the Se-compounds 1-11 and the chemotherapeutic drug doxorubicin.
The assay was carried out on MCF-7 and KCR breast cancer cell
lines. The adherent breast cancer cell lines were cultured in 96-well
flat-bottomed microtiter plates, using EMEM supplemented with
10% heat-inactivated fetal bovine serum. The density of the cells
was adjusted to 6×103 cells in 100 μI per well, the cells were seeded
for 24 h at 37˚C with 5% CO2 prior to the assay and then the
medium was removed from the plates containing the cells.
The final concentration of the Se-compounds and doxorubicin
used in the combination experiment was chosen in accordance with
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Figure 1. Chemical structure of the tested compounds. The number in parentheses denotes the position at which R1 is bound to the (hetero)aromatic ring.
their cytotoxicity towards these cell lines. The dilutions of
doxorubicin were made in a horizontal direction in 100 μl, and the
dilutions of the Se-compounds vertically in the microtiter plate in
50 μl volume. The plates were incubated for 72 h at 37˚C in 5%
CO2 atmosphere. The cell growth rate was determined after MTT
staining. At the end of the incubation period, 20 μl of MTT (Sigma)
solution (from a stock solution of 5 mg/ml) were added to each
well. After incubation at 37˚C for 4 h, 100 μl of SDS (Sigma)
solution (10% in 0.01 M HCI) were added to each well and the
plates were further incubated at 37˚C overnight. Optical density
(OD) was measured at 540/630 nm with Multiscan EX ELISA
reader (Thermo Labsystems). Combination index (CI) values at 50%
of the growth inhibition dose (ED50) were determined using
CompuSyn software (ComboSyn, Inc., Paramus, NJ, USA) to plot
four to five data points at each ratio. CI values were calculated by
means of the median-effect equation, according to the Chou–Talalay
method, where CI<1, CI=1, and CI>1 represent synergism, additive
effect (or no interaction), and antagonism, respectively (11,12).
Apoptosis induction. The ability of the Se-compounds to induce
apoptosis was determined on breast cancer cell lines. The apoptosis
assays were performed using Annexin V-FITC Apoptosis Detection
Kit from Calbiochem (EMD Biosciences, Inc. La Jolla, CA, USA),
following the instructions provided by the manufacturer. This assay
enables the quantification of early and late apoptotic events, as well
as necrosis and cell death in the cell population exposed to the Se-
compounds. The density of the cell suspension was adjusted to
1×106 cells/ml. The cell suspension was distributed into 0.5 ml
aliquots (5×105 cells) to a 24-well microplate and incubated
overnight at 37˚C in 5% CO2. On the following day, the medium
was removed, and fresh medium was added to the cells. The cells
were then incubated in the presence of Se-compounds at 2 μM for
3 h at 37˚C. 12H-Benzo[α]phenothiazine M627 (13), which is a
known early apoptosis inducer, was used as positive control. The
samples were washed in PBS and fresh medium was added to the
cells, followed by the incubation of the plate for 24 h at 37˚C, in
5% CO2. After the incubation period, the cells were trypsinized. The
harvested cells were centrifuged at 2000 × g for 2 minutes. The cells
were then re-suspended in fresh serum-free medium. Thereafter, the
apoptosis assay was carried out according to the rapid protocol of
the kit and the fluorescence was analyzed immediately using a
ParTec CyFlow flow cytometer (Partec, Munster, Germany).
Results 
The screening of the anticancer activity of Se-compounds in
MCF-7 cells indicated that selenoanhydride 1 and selenoesters
2-7 were not cytotoxic towards this cell line (Table I), as all
the IC50 values of these derivatives were above 100 μM. In
contrast, the ketone-containing selenoesters 9-11 had a potent
low-micromolar activity, as their IC50 values ranged from 1.04
to 1.70 μM, whereas the IC50 of the phenoxycarbonylmethyl
selenoester 7 was 64.8 μM. Results were similar for the
multidrug-resistant KCR cells except for two derivatives.
Firstly, in this case the IC50 of selenoanhydride 1, at a
concentration as low as 2.35 μM, which was more than 40-fold
lower that for MCF-7, suggesting that this compound acts
directly on ABCB1 overexpressed by KCR cells. Secondly,
compound 11 was close to 2-fold less active against KCR cells
compared to MCF-7 cells. None of compounds 12-15
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Figure 2. Interactions of the active Se-compounds with doxorubicin in KCR and MCF-7 cells. The figure indicates, at the most effective interaction
ratio (doxorubicin:Se-compound), the concentration of the Se-compound in the presence of doxorubicin at the concentration indicated; furthermore
the type of interaction (antagonism, additive effect and synergism) is also presented. 
evaluated for comparison studies exerted cytotoxic effects at
concentrations below 100 μM on any of KCR, MCF-7 and
MRC-5 cell lines evaluated. The anticancer effect of Se-
compounds on MRC-5 was determined previously (5).
Regarding the selectivity of the selenoesters towards
cancer cells, it was clearly observed that the ketone-
containing selenoesters exerted a moderate selectivity
towards MCF-7 and KCR cancer cells with respect to the
non-tumorous MRC-5 lung fibroblast cells (5), with the
exception of compound 11, which was slightly selective
towards KCR, exhibiting a SI of 2.2. The SI of compound 9
for KCR cells was approximately to 6 (SI=5.6), which was
the threshold for considering that a compound is strongly
selective. Remaining selenoesters lacked of selectivity due
to their poor activity against MCF-7 and KCR.
In contrast, selenoanhydride (1) was strongly selective
towards KCR cells in comparison to the non-tumorous
fibroblast cells with SI of 42 (7-fold higher the threshold). 
The five active compounds in the cytotoxicity assay were
evaluated in combination with doxorubicin (Figure 2).
Results were quite fascinating as they showed a marked
difference between the two tested cell lines. All Se-
compounds assayed exerted synergistic interactions with
doxorubicin against the KCR cell line, whereas all the
observed interactions of the selenoesters with doxorubicin
against the MCF-7 cell line were antagonistic. 
Against KCR cells, compound 9 was undoubtedly the most
profitable in the combination assay, as it existed the highest
grade of synergy among all evaluated compounds and at the
lowest concentrations of both Se-compound (2.5 μM) and
doxorubicin (42.5 μM). The remaining Se-compounds
interacted in a synergistic manner with doxorubicin at a
concentration of compound and drug four- and two-fold
higher, respectively. Against MCF-7 cells, compound 9
interacted in a moderately antagonistic manner at higher
concentration (5 μM). Slight antagonism was observed for
compound 8 at the same concentration, but the concentration
of doxorubicin was in this case four times higher. 
Finally, the compounds were not able to induce significant
apoptotic events in MCF-7 and KCR cells; with the
exception of the phenoxycarbonylmethyl selenoester 7 in
MCF-7 cells. This derivative, at a low concentration (2 μM),
triggered early apoptotic and late apoptotic/necrotic events
in 16.9% and 7.85% of cells (Figure 3). This apoptosis-
inducing activity was moderate, as reference compound
M627 induced 20.8% and 67.1% events, respectively. 
Discussion
Conventional chemotherapy in the treatment of early and
metastatic breast cancer is partly based on the administration
of anthracycline drugs e.g. doxorubicin. Since these drugs
provoke side-effects such as cardiotoxicity and
myelosuppression (14, 15), there is an urgent need to
minimize the side-effects. In order to reduce the adverse
effect of anthracyclines, several alternatives could be
applied, for example the use of liposomal doxorubicin (16),
nanotechnology (17) and preparation of less toxic
derivatives. 
In this study, we investigated the cytotoxic properties of
Se-compounds and their interaction with doxorubicin in
order to find effective adjuvants for combination
chemotherapy using doxorubicin with Se-compounds.
As commented in the previous section, selenoanhydride 1
exerted selective activity towards the resistant KCR cell line
overexpressing ABCB1 (IC50=2.35 μM), as it was
ANTICANCER RESEARCH 39: xxx-xxx (2019)
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Table I. Cytotoxic activity of Se-compounds against MCF-7 and doxorubicin-resistant KCR breast cancer cell lines. 
Compound                     MCF-7                                          KCR                      SI MCF                     MRC-5*                                         SI
                                                                                                                            7/KCR
                        IC50 (μM)          ±SD              IC50 (μM)             ±SD                                IC50 (μM)         ±SD         MRC-5/MCF-7        MRC-5/KCR
1                           >100                  -                       2.35                  0.47                ≥42              >100                 -                        -                            ≥42
2                           >100                  -                      >100                     -                     -                  4.26               0.65                 ≤0.04                      ≤0.04
3                           >100                  -                      >100                     -                     -                  17.9               0.00                 ≤0.18                      ≤0.18
4                           >100                  -                      >100                     -                     -                  28.4               0.70                 ≤0.28                      ≤0.28
5                           >100                  -                      >100                     -                     -                  61.5               2.16                 ≤0.62                      ≤0.62
6                           >100                  -                      >100                     -                     -                  76.6               0.92                 ≤0.77                      ≤0.77
7                           >100                  -                      >100                     -                     -                  33.4               3.08                 ≤0.33                      ≤0.33
8                            64.8                16.7                    82.2                  15.7               0.79              >100                 -                     ≥1.5                        ≥1.2
9                            1.04                0.47                    0.96                   0.18               1.08               5.35               0.24                   5.2                           5.6
10                          1.70                0.45                    1.75                   0.15               0.97               8.10               0.90                   4.8                           4.6
11                          1.45                0.23                    2.37                   0.30               0.61               5.04               0.71                   3.5                           2.2
IC50: 50% Inhibitory concentration; SI: selectivity index. For cytoxicity, IC50 values in bold denote IC50 values below 5 μM, and those in italics,
values between 5 and 10 μM. In selectivity, values in bold denote a strong selectivity, and in italics, a moderate selectivity. Compounds 12-15 were
not included as their IC50 values for the three cell lines were above 100 μM. *Values taken from a previous study (5).
ineffective against MCF-7 and MRC-5 (non-tumor lung
fibroblast) cells. These results are in accordance with our
previous data confirming that selenoanhydride 1 interacts
directly with ABCB1 (5,6). Surprisingly, this derivative was
unable to trigger apoptotic events in the tested breast cancer
cell lines, probably due to a dual inhibition of ABCB1 and
multidrug resistance protein 1 efflux pumps, however, other
resistance mechanisms are also involved.
Among the selenoesters, only the ketone-containing
selenoesters 9-11 exerted significant cytotoxic activity
against these two cell lines. Symmetrical dimethyl
selenodiesters 2-5 were inactive, as were amide-containing
selenoester 6 and methoxycarbonylmethyl selenoester 7. In
the latter, the replacement of the methyl moiety bound to the
oxygen of the O-ester by a phenyl ring lowers the IC50 but
still at a level of between 60 and 100 μM. When this phenyl
ester is replaced by a methylketone (9) or tert-butylketone,
then the activity increases dramatically, this time lowering
the IC50 to low micromolar concentrations, pointing to the
crucial role of this alkylketone moiety in the biological
activity of ketone-containing selenoesters. Furthermore,
these promising selenium derivatives exerted noteworthy
Csonka et al: Selenocompounds Against Breast Cancer
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Figure 3. Apoptosis induction by compound 7 in MCF-7 cells compared
to the positive control 12H-[α]benzophenothiazine. Q1: dead cells; Q2:
cells undergoing late apoptosis/necrosis; Q3: cells undergoing early
apoptosis; Q4: healthy, living cells.
selectivity towards the evaluated cancer cells (MCF 7, KCR)
rather than the non-tumorous cell line MRC 5.
The results observed in combination assays are
astonishing, in that they point to differential activity in the
two cell lines, the resistant (KCR) one in this case being more
sensitive to the action of the compounds. It has been shown
that doxorubicin and methylseleninic acid act synergistically
on MCF-7 cells, inducing apoptosis because doxorubicin and
selenium cooperatively activate first apoptosis signal (FAS)
pathway. Doxorubicin causes Fas oligomerization in a FasL-
independent manner and methylseleninic acid increases FAS-
associated death domain protein expression together
triggering apoptosis (18). Out of our 11 Se-compounds, only
methoxycarbo-nylmethyl p-chlorobenzoselenoate (7) induced
apoptosis of MCF-7 cells, the other derivatives were not
capable of provoking apoptosis of MCF-7 and KCR cells.
This is very relevant as it suggests that these derivatives
might have the ability to overcome some aspects of resistance
of KCR cells. Since the derivatives are proven ABCB1
modulators, their synergism with doxorubicin might be due to
their interaction with this efflux pump overexpressed by KCR
cells. On the contrary, the explanation of their antagonism
with doxorubicin in MCF-7 cells is the involvement of other
resistance mechanisms and cellular processes. This could open
a new and straightforward approach to treat ABCB1-
expressing resistant breast cancer that is resistant to the
treatments currently in clinical use. The methylketone
selenoester 9 would in such cases be the most promising
compound. Its activity makes it worth investigating in more
depth for potential applications of this compound and of
closely related new derivatives (which could be synthesized
in future work) with intrinsic anticancer activity as sensitizers
of resistant cancer.
Overall, the results obtained herein highlight the
importance for biological activity of the -COSeCH2COCH3
and -COSeCH2CO(CH3)3 moieties in comparison with the
remaining substituents considered -COSeCH3, -COSeCH2CO
NH2, -COSeCH2COOCH3, and -COSeCH2COPh. The good
cytotoxic activity, selectivity and ability to modulate the
effect of doxorubicin found for the ketone-containing
selenoesters 9-11 against the two breast cancer cell lines
evaluated are in agreement with previous work of our group
on mouse T-lymphoma cells and colonic adenocarcinoma
cells (5, 6) and draw the attention to this privileged moiety.
In future studies it will be necessary to obtain and evaluate
more compounds with these moieties in order to ascertain
what substituents in the phenyl ring bound to the carbonyl of
the selenoester enhance activity, with the aim of designing
more potent and selective anticancer agents.
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